Matrix therapy is a cost-effective solution to reduce amputation risk and improve quality of life: pilot and case studies.
CACIPLIQ20
Matrix therapy
OTR4120
ischemic skin ulcers
Journal
Regenerative medicine research
ISSN: 2050-490X
Titre abrégé: Regen Med Res
Pays: England
ID NLM: 101638057
Informations de publication
Date de publication:
2019
2019
Historique:
received:
07
10
2019
accepted:
11
11
2019
entrez:
11
12
2019
pubmed:
11
12
2019
medline:
11
12
2019
Statut:
ppublish
Résumé
Chronic, non-healing ulcers remain one of the most challenging clinical situations for health care practitioners. Often, conventional treatments fail and lead to amputation, further decreasing the patient's quality of life and resulting in enormous medical expenditures for healthcare systems. Here we evaluated the use of and cost-effectiveness of the RGTA (ReGeneraTing Agents) medical device CACIPLIQ20 (OTR4120) for chronic lower-extremity ulcers in patients with Leriche and Fontaine Stage IV peripheral arterial disease who were not eligible for revascularization. This uncontrolled pilot study included 14 chronic lower extremity ulcers in 12 patients in one hospital. The pilot study included 12 patients with TcPO A 35% reduction in ulcer size was achieved after 4 weeks. 7 (50%) out of 14 ulcers completely healed within 1 to 3 months of treatment. OTR4120 is an effective therapeutic option for patients with chronic lower extremity ulcers, can provide major improvement of quality of life and has the added benefit of being a significant cost-effective solution for healthcare systems.
Identifiants
pubmed: 31821145
doi: 10.1051/rmr/190002
pii: rmr190002
pmc: PMC6902838
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2Informations de copyright
© P. Desgranges et al., published by EDP Sciences, 2019.
Références
Int Wound J. 2016 Apr;13(2):272-82
pubmed: 26695998
Clin Case Rep. 2019 Feb 17;7(4):619-625
pubmed: 30997049
Perspect Clin Res. 2013 Jan;4(1):49-52
pubmed: 23533982
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Arch Phys Med Rehabil. 2005 Mar;86(3):480-6
pubmed: 15759232
FASEB J. 2000 Nov;14(14):2133-4
pubmed: 11024002
J Fr Ophtalmol. 2008 May;31(5):465-71
pubmed: 18641578
Wound Repair Regen. 2011 Jul-Aug;19(4):505-14
pubmed: 21649786
N Engl J Med. 2017 Oct 19;377(16):1559-1567
pubmed: 29045216
Burns. 2001 Jun;27(4):349-58
pubmed: 11348743
J Biomed Mater Res A. 2009 Sep 1;90(3):641-7
pubmed: 18563829
Br J Dermatol. 1990 Oct;123(4):507-14
pubmed: 2151304
Clin Case Rep. 2018 Sep 14;6(11):2061-2069
pubmed: 30455892
J Rehabil Res Dev. 2014;51(8):1325-30
pubmed: 25625913
FASEB J. 1999 Apr;13(6):761-6
pubmed: 10094936
BMC Health Serv Res. 2009 Jul 10;9:115
pubmed: 19591680
Clin Podiatr Med Surg. 2002 Oct;19(4):483-91
pubmed: 12471856